Left Menu
Development News Edition

Gilead raises sales outlook to include COVID-19 treatment remdesivir

a positive that was not expected at the start of the year," said Jefferies analyst Michael Yee. Gilead's second-quarter sales fell nearly 10% from a year earlier to $5.1 billion, short of the average analyst estimate of $5.3 billion, according to Refinitiv. The results reflected weak sales of Gilead's hepatitis C drugs and flagship HIV treatments during coronavirus pandemic lockdowns.

Reuters | Updated: 31-07-2020 04:46 IST | Created: 31-07-2020 04:46 IST
Gilead raises sales outlook to include COVID-19 treatment remdesivir

Gilead Sciences Inc on Thursday posted worse-than-expected quarterly results, but raised its 2020 sales forecast to include revenue from its antiviral drug remdesivir, one of the only treatments shown to help COVID-19 patients. Gilead said it expects total 2020 sales of $23 billion to $25 billion, up from its previous range of $21.8 billion to $22.2 billion.

"We think this implies up to $1 billion to $3 billion of remdesivir, ... a positive that was not expected at the start of the year," said Jefferies analyst Michael Yee. Gilead's second-quarter sales fell nearly 10% from a year earlier to $5.1 billion, short of the average analyst estimate of $5.3 billion, according to Refinitiv.

The results reflected weak sales of Gilead's hepatitis C drugs and flagship HIV treatments during coronavirus pandemic lockdowns. The company said it expects its HIV drugs and hepatitis C sales to begin regaining momentum in the current third quarter. Adjusted earnings for the second quarter of $1.11 per share fell short of analysts' average estimate by 34 cents.

Shares of Gilead, which closed up about 1% in regular trading, were down 3.5% at $69.80 in extended trading. Second-quarter sales of Gilead's HIV drugs fell 1% from a year earlier to $4 billion, while sales of drugs to cure hepatitis C fell 47% to $448 million due to fewer new patients and competition from rival drugs. Gilead this month began commercial sales of remdesivir, which is given to hospitalized patients by infusion. The drug was granted emergency use authorization by the U.S. Food and Drug Administration in May after it demonstrated an ability to shorten hospital stays for COVID-19 patients, but does not yet have full U.S. approval. It was approved in Japan.

Demand for remdesivir continues to outstrip supply in many parts of the world. Gilead's chief executive, Daniel O'Day, on a conference call, said the company expects by the end of September to be producing enough remdesivir to meet real-time global demand.

Gilead said it still expects to manufacturer 2 million or more remdesivir treatment courses cumulatively in 2020, and its revenue outlook reflects expected sales of up to 1.5 million courses this year. The company said it has launched a clinical trial of an inhaled formulation of remdesivir, with the aim of more effectively delivering the drug to lung tissue. Gilead also plans to study the drug in patients with earlier-stage COVID-19.

The U.S. National Institute of Allergy and Infectious Diseases is currently conducting a trial of remdesivir in combination with Olumiant, an arthritis drug from Eli Lilly & Co , and those results are expected next month. So far, only remdesivir and the generic steroid dexamethasone have been shown in rigorous clinical trials to help patients with COVID-19.

(Reporting By Deena Beasley and Michael Erman; Editing by Bill Berkrot and Leslie Adler)


TRENDING

OPINION / BLOG / INTERVIEW

Post-COVID-19 Nigeria needs a robust Health Management Information System to handle high disease burden

Nigeria is among a few countries that conceptualised a health management information system HMIS in the early 90s but implementation has been a challenge till date. Besides COVID-19, the country has a huge burden of communicable and non-com...

Morocco COVID-19 response: A fragile health system and the deteriorating situation

Learning from its European neighbors, Morocco imposed drastic measures from the initial stages of the COVID-19 outbreak to try to contain its spread. The strategy worked for a few months but the cases have surged after mid-June. In this sit...

COVID-19: Argentina’s health system inefficiencies exaggerate flaws of health information system

You can recover from a drop in the GDP, but you cant recover from death, was the straightforward mindset of Argentinas President Alberto Fernndez and defined the countrys response to COVID-19. The South American nation imposed a strict...

Rwanda’s COVID-19 response commendable but health information system needs improvement

Rwanda is consistently working to improve its health information system from many years. However, it is primarily dependent on the collection and reporting of health data on a monthly basis. Besides, evaluation studies on Rwandas HIS publis...

Videos

Latest News

One terrorist killed by security forces in J-K's Pulwama

One terrorist has been gunned down by security forces in an operation in Macchihom in Jammu and Kashmirs Pulwama district on Thursday. According to the Northern Command, Indian Army the operation is in progress.Op Macchihom Pulwama. One ter...

LG unveils two new budget phones- K52 and K62 with 48MP quad-cam; 4,000mAh battery

LG has introduced two new affordable K-series smartphones- LG K52 and LG K62. Both the budget-friendly phones come with HD FullVision Display, 48-megapixel quad-camera setup, octa-core processors and a 4,000mAh battery.Starting next month, ...

Maruti Suzuki launches car subscription plan in Delhi NCR, Bengaluru

Maruti Suzuki on Thursday launched its vehicle subscription programme for people in Delhi, NCR Noida, Ghaziabad, Faridabad, Gurugram and Bengaluru in a move to offer easy and flexible car ownership for customers.This initiative allows a cus...

FACTBOX-Latest on the worldwide spread of coronavirus

Canada entered a second wave of the COVID-19 pandemic and cases continued to rise across the hard-hit Latin American region, while a raft of lacklustre data from major global economies revived concerns about the resilience of an economic re...

Give Feedback